Long-term retrospective study on the conversion rate from prediabetes to diabetes in transfusion dependent thalassemia (TDT) patients: the experience of a single tertiary care Center in Iran
Thalassemia and conversion rate of prediabetes to diabetes
Keywords:
Transfusion-dependent thalassemia (TDT), prediabetes, diabetes mellitus, progression rate, risk factors, Iran.Abstract
ackground: The prevalence of glucose dysregulation (GD) in patients with thalassemia increases with age. Objectives: This retrospective study aimed to characterize the natural history of prediabetes and identify risk factors associated with the progression to diabetes among transfusion-dependent thalassemia (TDT) patients. Research Design and Methods: We retrospectively reviewed annual oral glucose tolerance test (OGTT) data from 108 out of 700 Iranian TDT patients diagnosed with diabetes mellitus (DM). Results: Prediabetes was diagnosed at a mean age of 21.3 ± 5.9 years. The mean serum ferritin (SF) level at prediabetes diagnosis was 3,869 ± 2,805 ng/mL. The average time for conversion from prediabetes to DM was 3.8 ± 2.0 years, with a mean age of 25.0 ± 6.5 years at DM diagnosis. A parental history of diabetes was reported in 87% of the patients. There was a direct correlation between the age at prediabetes diagnosis and the age at DM diagnosis (r = 0.9391, P: < 0.00001), as well as with fasting plasma glucose (FPG) at DM diagnosis (r = 0.7065, P: < 0.00001). SF levels at prediabetes diagnosis were also associated with SF levels at the time of DM diagnosis. Conclusions: Identifying high-risk patients remains challenging; however, a parental history of diabetes, elevated SF levels, and younger age at prediabetes diagnosis were significantly associated with the progression to DM in TDT patients with a normal body mass index.
References
Taher A, Vichinsky E, Musallam K, et al. Weatherall D, editor. Nicosia (Cyprus): Thalassaemia International Federation; 2013.
De Sanctis V, Soliman A, Tzoulis P, et al. Prevalence of glucose dysregulation (GD) in patients with β-thalassemias in different countries: A preliminary ICETA survey. Acta Biomed. 2021;92:(3): e2021240.doi: 10.23750/abm.v92i3.11733.
Diabetes Canada Clinical Practice Guidelines Expert Committee. Punthakee Z, Goldenberg R, Katz P. Definition, Classification and Diagnosis of Diabetes, Prediabetes and Metabolic Syndrome. Can J Diabetes. 2018;42 (Suppl.1):S10–S5. doi: 10.1016/j.jcjd.2017.10.003.
De Sanctis V, Soliman AT, Daar S, Di Maio S, Elsedfy H, Kattamis C. For Debate: Assessment of HbA1c in transfusion dependent thalassemia patients.Pediatr Endocrinol Rev. 2020;3:226-34.doi:10.17458/per. vol17.2020fd.ssd.HbA1cthalassemia.
Choudhary A, Giardina P, Antal Z, Vogiatzi M. Unreliable oral glucose tolerance test and HbA1C in Beta Thalassaemia Major-A case for continuous glucose monitoring? Br J Haematol. 2013 ; 162(1):132–5. doi: 10.1111/bjh.12322.
Sacks DB. Hemoglobin variants and hemoglobin A1C analysis: problem solved? Clin Chem. 2003; 49:1245–7. doi.org/10.1373/49.8.1245.
Spencer DH, Grossman BJ, Scott MG. Red cell transfusion decreases hemoglobin A1C in patients with diabetes. Clin Chem. 2011;57:344–6.doi.org/10.1373/clinchem.2010.157321.
American Diabetes Association. Classification and diagnosis of diabetes: Standards of medical care in diabetes - 2020. Diabetes Care. 2020; 43(Suppl.1): S14-S31.doi.org/10.2337/dc20-S002.
World Health Organization. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: report of a WHO/IDF consultation. Geneva: World Health Organization; 2006. pp. 1–50.
Saeedi P, Petersohn I, Salpea P, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9(th) edition. Diabetes Re Clin Pract. 2019;157:107843. doi: 10.1016/j.diabres.2019.107843.
Omar MAK, Motala AA. Variability in the natural history of impaired glucose tolerance (IGT):Population differences. Int J Diab Dev Countries.1996;16:3-10.doi: not available.
Weiss R, Santoro N, Giannini C, Galderisi A, Umano GR, Caprio S. Prediabetes in youth - mechanisms and biomarkers. Lancet Child Adolesc Health. 2017;1(3):240–8. doi:10.1016/ S2352-4642(17)30044-5.
Kattamis C, Ladis V, Tsoussis D, Kaloumenou I, Theodoridis C. Evolution of glucose intolerance and diabetes in transfused patients with thalassemia. Pediatr Endocrinol Rev. 2004;2 (Suppl 2):267-71.PIMD:16462709.
De Sanctis V, Daar S, Soliman AT, Tzoulis P, Yassin MA, Kattamis C. Evolution of combined impaired fasting glucose and impaired glucose tolerance in β-thalassemia major: Results in 58 patients with a mean 7.7- year follow-up. Acta Biomed. 2022;93 (3): e2022242.doi: 10.23750/abm.v93i3.12825.
De Sanctis V, Daar S, Soliman AT, et al. Screening for glucose dysregulation in β-thalassemia major
(β-TM): An update of current evidences and personal experience. Acta Biomed. 2022; 93 (1): e2022158.doi: 10.23750/abm.v93i1.12802.
De Sanctis V, Soliman AT. ICET-A an Opportunity for Improving Thalassemia Management. J Blood Disord. 2014;1(1): 2. doi: not available.
De Sanctis V, Daar S, Soliman AT, Campisi S, Tzoulis P. Long-term retrospective study on the progression of prediabetes to diabetes mellitus in transfusion dependent β-thalassemia (β-TDT) patients: The experience in Oman and Italy. Acta Biomed. 2024 (accepted for publication).
August GP, Caprio S, Fennoy I, et al. Prevention and treatment of pediatric obesity: An endocrine society clinical practice guideline based on expert opinion. J Clin Endocrinol Metab, 2008;93:4576-99. doi:10. 1210/ jc. 2007-2458.
De Sanctis V, Soliman AT, Yassin MA, et al. Hypogonadism in male thalassemia major patients: pathophysiology, diagnosis and treatment. Acta Biomed. 2018;89:6–15. doi: 10.23750/abm.v89i2-S.7082
De Sanctis V, Soliman AT, Elsedfy H, et al. Growth and endocrine disorders in thalassemia: The international network on endocrine complications in thalassemia (I-CET) position statement and guidelines. Indian J Endocrinol Metab. 2013;17:8–18.doi.10.4103/2230-8210.107808.
De Sanctis V, Vullo C, Bagni B, Chiccoli L. Hypoparathyroidism in beta-thalassemia major. Clinical and laboratory observations in 24 patients. Acta Haematol. 1992;88:105–8. doi: 10.1159/000204662.
De Sanctis V, Soliman AT, Elsedfy H, et al. The ICET-A Survey on current criteria used by clinicians for the assessment of central adrenal insufficiency in thalassemia: Analysis of results and recommendations. Mediterr J Hematol Infect Dis. 2016;8(1):e2016034. doi: 10.4084/ MJHID. 2016.034.
Munkongdee T, Chen P, Winichagoon P, Fucharoen S, Paiboonsukwong K. Update in laboratory Diagnosis of thalassemia. Front Mol Biosci. 2020;7:74.doi.10.3389/fmolb.202000074.
Addison FM, Beamish MR, Hales CN, Hodgkins M, Jacobs A, Llewellin P. An immunoradioactive assay for ferritin in serum in normal subjects and patients with iron deficiency and iron overload. J Clin Pathol. 1972;35:326–31. doi: 10.1136/jcp.25.4.326.
Hadipour Dehshal M, Tabrizi Namini M, Hantoushzadeh R, Yousefy Darestani S. β-thalassemia in Iran: Things everyone needs to know about this disease. Hemoglobin. 2019,43(3):16673. doi:10. 1080/ 03630269. 2019.1628774.
Rahimi A. Genetic Epidemiology, hematological and clinical features of hemoglobinopathies in Iran. Biomed Res Int. 2013;2013:803487. doi: 10.1155/2013/803487.
Fonseca VA. Defining and characterizing the progression of type 2 diabetes. Diabetes Care. 2009;32(Suppl 2):S151‐S6.doi:10.2337/dc09-S301.
DeJesus RS, Breitkopf CR, Rutten LJ, Jacobson DJ, Wilson PM, Sauver JS. Incidence rate of prediabetes progression to diabetes: modeling an optimum target Group for Intervention. Popul Health Manag. 2017;20 (3):216‐23. doi:10.1089/pop.2016.0067.
Tabak AG, Herder C, Rathmann W, Brunner EJ, Kivimaki M. Prediabetes: a high-risk state for diabetes development. Lancet. 2012;379:2279–90. doi: 10.1016/S0140-6736(12)60283-9.
De Sanctis V, Daar S, Soliman AT, Tzoulis P, Yassin MA, Kattamis C. Evolution of combined impaired fasting glucose and impaired glucose tolerance in β-thalassemia major: Results in 58 patients with a mean 7.7- year follow-up. Acta Biomed. 2022;93 (3): e2022242. doi:10.23750/ abm.v93i3.12825.
De Sanctis V, Daar S, Soliman AT, et al. Screening for glucose dysregulation in β-thalassemia major (β-TM): An update of current evidences and personal experience. Acta Biomed. 2022;93(1): e2022158.doi: 10. 23750/abm.v93i1.12802.
Bartnik M, Ryden L, Ferrari R, et al. The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe: The Euro Heart Survey on diabetes and the heart. Eur Heart J. 2004;25(21):1880-90. doi:10.1016/j.ehj.2004.07.027.
Marsella M, Borgna-Pignatti C, Meloni A, et al. Cardiac iron and cardiac disease in males and females with transfusion dependent thalassemia major: a T2* magnetic resonance imaging study. Haematologica. 2011;96(4):515–20. doi:10.3324/haematol.2010.025510.
Daar S, Al-Naamani K, De Sanctis V, et al. Mortality and complications in Omani patients with beta-thalassemia major: a long-term follow-up study. Acta Biomed. 2023;94 (4): e2023191.doi: 10. 23750/ abm. v94i4.14856.
Zhou YL, Zhang XH, Liu TN, Wang L, Yin XL. Splenectomy improves anaemia but does not reduce iron burden in patients with haemoglobin HC onstant Spring disease. Blood Transfus. 2014;12:471–8. doi.org/10.2450%2F2014.0247-13.
Kolnagou A, Michaelides Y, Kontoghiorghe CN, Kontoghiorghes GJ. The importance of spleen, spleen iron, and splenectomy for determining total body iron load, ferrikinetics, and iron toxicity in thalassemia major patients. Toxicol Mech Methods. 2013;23:34–41.doi: 10.3109/15376516.2012.735278.
Cho N, Shaw J, Karuranga S, et al. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract. 2018;138:271–81. doi: 10.1016/j.diabres.2018.02.023.
Khodakarami R, Abdi Z, Ahmadnezhad E, Sheidaei A, Asadi-Lari M. Prevalence, awareness, treatment and control of diabetes among Iranian population: results of four national cross-sectional STEPwise approach to surveillance surveys, BMC Public Health. 2022; 22:1216. doi: 10.1186/s12889-022-13627-6.
Hwalla N, Jaafar Z, Sawaya S. Dietary management of type 2 diabetes in the MENA region: A review of the evidence. Nutrients. 2021;13(4):1060.doi: 10.3390/nu13041060.
El-Kebbi IM, Bidikian NH, Hneiny L, Nasrallah MP. Epidemiology of type 2 diabetes in the Middle East and North Africa: Challenges and call for action. World J Diabetes. 2021;12(9):1401. doi: 10.4239/wjd.v12. i9.1401.
Bahar A, Kashi Z, Sohrab M, Kosaryan M, Janbabai G. Relationship between beta-globin gene carrier state and insulin resistance. J Diabetes Metab Disord. 2012; 11:2.doi.10.1186/s40200-015-0129-2.
Rujito L, Fauziyah F, Azizah EF, et al. Scanning SNPs of Diabetes Mellitus related genes; HNF4A, PTPN, KCNJ11, PPAR gamma; among Thalassemia Patients: a Preliminary Study. IOP Conf. Series: Earth and Environment Sci.2019; 255:012008. doi:10.1088/1755-1315/255/1/012008.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Vincenzo De Sanctis, Forough Saki, Mehran Karimi, Ashraf Soliman, Shahina Daar, Ploutarchos Tzoulis
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.
How to Cite
